CIAMBRA 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/08/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
N/0007 
Minor change in labelling or package leaflet not 
14/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
R/0006 
Renewal of the marketing authorisation. 
28/05/2020 
23/07/2020 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
CIAMBRA in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0005/G 
This was an application for a group of variations. 
13/06/2019 
23/09/2019 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0004/G 
This was an application for a group of variations. 
16/10/2018 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.d.1.b.1 - Stability of AS - Change in the storage 
conditions - Change to more restrictive storage 
conditions of the AS 
B.I.d.1.c - Stability of AS - Change in the re-test 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period or storage conditions - Change 
to an approved stability protocol 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
03/08/2018 
23/09/2019 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
II/0002/G 
This was an application for a group of variations. 
06/07/2017 
n/a 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
17/02/2017 
15/01/2018 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
